Bloqcube and NTT DATA Partner to Deliver Blockchain-Driven Management Solutions
BloqCube, a developer of a proprietary integrated clinical trial and financial management system employing innovative blockchain technology, and NTT DATA announced an alliance to benefit the healthcare and life sciences industry.
BloqCube will bring to the partnership its pioneering technology that speeds up clinical trials, by enhancing efficiencies of multiple related processes while retaining strong data security. NTT DATA will provide its expertise in enterprise-scale domain consulting, application implementation and integration services through the company’s healthcare and life sciences business consulting and blockchain technology competencies.
BloqCube uses proprietary algorithms to automate what is typically a laborious process of monitoring clinical trial sites (hospitals, treatment centers) and verifying data. Its C2TA technology delivers real-time accounting transaction records of payments and financial planning to clinical trial management. BloqCube is the first company to offer a fully integrated clinical management system leveraging blockchain technology to ensure data security and integrity while accelerating clinical trials and cutting costs.
BloqCube will benefit from NTT DATA’s experience in accelerating value-based healthcare, maximizing efficiency and delivering flexible solutions to achieve accuracy and customer satisfaction.
BloqCube CEO Rama K. Rao stated, “We are delighted to work with NTT DATA as both our organizations are clearly focused on improving patient outcomes. NTT DATA has a broad client base in the healthcare and life sciences industry that will be able to take advantage of our first-in-class clinical trial and financial management technology while BloqCube clients will benefit from NTT DATA’s enterprise-scale services.”
BloqCube participated in the New Jersey Innovation Institute (NJII), Health IT Connections program that connects health IT innovators with leading healthcare corporations, like NTT DATA. NJII’s Health IT Connections program is funded in part from JPMorgan Chase’s Small Business Forward initiative.
FDA Finalizes Decentralized Clinical Trial Guidance
November 25th 2024The FDA's guidance is part of a broader effort to modernize clinical trials, improve efficiency, reduce participant burden, and expand access, particularly for underrepresented populations and those in geographically or economically constrained areas.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Patient Engagement Platform Checklist
November 22nd 2024Modern clinical trials are more complex than ever, and one significant reason is the increased focus on patient engagement. Incorporating a patient engagement platform into your clinical trial enhances the patient experience and can lead to more successful trials with stronger, more reliable outcomes. We put together this helpful checklist of key features to look out for when choosing a platform for your study.
The Rise of Predictive Engagement Tools in Clinical Trials
November 22nd 2024Patient attrition can be a significant barrier to the success of a randomized controlled trial (RCT). Today, with the help of AI-powered predictive engagement tools, clinical study managers are finding ways to proactively reduce attrition rates in RCTs, and increase the effectiveness of their trial. In this guide, we look at the role AI-powered patient engagement tools play in clinical research, from the problems they’re being used to solve to the areas and indications in which they’re being deployed.
